The main objective of the study consists in characterizing the immune cells that are
present/persist in the skin and the blood of atopic dermatitis (AD) patients treated with
Dupilumab, as well as with potent/very potent topical corticosteroids (TCS: betamethasone
valerate cream 0.1% or clobetasol propionate cream 0.05%). A specific attention will be paid
on the presence/persistence of skin Trm and ILCs.
The study population will consist of 20 adult patients suffering from moderate to severe
Atopic Dermatitis and eligible for Dupilumab treatment. (Patients should have inadequate
response, intolerance or contraindication to systemic anti-inflammatory treatments).
This is an exploratory, prospective, single-site, randomized, open labeled study. There is a
treatment period of 168 days (24 weeks) and a post-treatment follow-up period of maximum 102
days.
Phase:
N/A
Details
Lead Sponsor:
Association pour la Recherche Clinique et Immunologique